Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes

被引:4
作者
Lashay, Alireza [1 ]
Riazi-Esfahani, Hamid [1 ]
Faghihi, Hooshang [1 ]
Mirshahi, Ahmad [1 ]
Khojasteh, Hassan [1 ]
Khodabande, Alireza [1 ]
Amoli, Fahimeh Asadi [1 ]
Ghassemi, Fariba [1 ]
Bazvand, Fatemeh [1 ]
Pour, Elias Khalili [1 ]
Ebrahimiadib, Nazanin [1 ]
Torkashvand, Ali [1 ]
Delrish, Elham [1 ]
机构
[1] Univ Tehran Med Sci, Farabi Eye Hosp, Eye Res Ctr, Tehran, Iran
关键词
DIABETIC-RETINOPATHY; COST-EFFECTIVENESS; BEVACIZUMAB; RANIBIZUMAB; DRUGS;
D O I
10.1155/2020/2602918
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. To assess the safety of biosimilar intravitreal aflibercept (CinnaGen Co., Iran) compared to the reference product (Eylea (R); Bayer Schweiz AG, Zurich, Switzerland) in rabbit eyes through functional and histologic studies. Methods. Forty New Zealand albino rabbits were recruited to the study and were divided into four groups to be sacrificed at 48 hours, one, two, and four weeks after injections. In each group, five rabbits received 0.05 mL (2 mg) biosimilar aflibercept in the right eye and 0.05 mL saline in the left eye as the control, and in a similar manner, the remaining five rabbits received the reference drug in the right eye and saline in the left eye. All the rabbits underwent comprehensive ophthalmic examination and electroretinography (ERG) tests at baseline and also just before enucleation at the specific predefined time points. The enucleated eyes were prepared for retinal toxicity histological examination. Results. No retinal toxicity was observed based on histologic and ERG findings in all groups. Choroidal congestion was revealed after 1 week in an eye that was injected with biosimilar aflibercept, although the similar finding was detected in the contralateral eye which received saline. Also, one subject which received the reference drug showed chronic vitritis and lymphoplasmocytic reaction of the optic disc at week 4. The remaining subjects showed no histologic changes. Conclusion. The 2 mg intravitreal injection of biosimilar aflibercept (CinnaGen Co., Iran) was found to be nontoxic in rabbit eyes in the short-term period. Further studies are required to warrant the efficacy and safety profile of the drug in human subjects.
引用
收藏
页数:6
相关论文
共 28 条
[21]   Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial [J].
Ross, Eric L. ;
Hutton, David W. ;
Stein, Joshua D. ;
Bressler, Neil M. ;
Jampol, Lee M. ;
Glassman, Adam R. .
JAMA OPHTHALMOLOGY, 2016, 134 (08) :888-896
[22]   Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies [J].
Schmidt-Erfurth, Ursula ;
Kaiser, Peter K. ;
Korobelnik, Jean-Francois ;
Brown, David M. ;
Chong, Victor ;
Quan Dong Nguyen ;
Ho, Allen C. ;
Ogura, Yuichiro ;
Simader, Christian ;
Jaffe, Glenn J. ;
Slakter, Jason S. ;
Yancopoulos, George D. ;
Stahl, Neil ;
Vitti, Robert ;
Berliner, Alyson J. ;
Soo, Yuhwen ;
Anderesi, Majid ;
Sowade, Olaf ;
Zeitz, Oliver ;
Norenberg, Christiane ;
Sandbrink, Rupert ;
Heier, Jeffrey S. .
OPHTHALMOLOGY, 2014, 121 (01) :193-201
[23]   Biosimilars in ophthalmology: "Is there a big change on the horizon?" [J].
Sharma, Ashish ;
Reddy, Prahalad ;
Kuppermann, Baruch D. ;
Bandello, Francesco ;
Lowenstein, Anat .
CLINICAL OPHTHALMOLOGY, 2018, 12 :2137-2143
[24]  
Shinoda K, 2000, CURR EYE RES, V21, P655, DOI 10.1076/0271-3683(200008)21:2
[25]  
1-V
[26]  
FT655
[27]   Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study [J].
Wong, Tien Yin ;
Ogura, Yuichiro ;
Lee, Won Ki ;
Iida, Tmohiro ;
Chen, Shih-Jen ;
Mitchell, Paul ;
Cheung, Chui Ming Gemmy ;
Zhang, Zhongqi ;
Leal, Sergio ;
Ishibashi, Tatsuro .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 204 :80-89
[28]   Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients [J].
Ziemssen F. ;
Lüke M. ;
Messias A. ;
Beutel J. ;
Tatar O. ;
Zrenner E. ;
Bartz-Schmidt K.U. .
International Ophthalmology, 2008, 28 (2) :101-109